Navigation Links
QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers
Date:9/5/2011

GERMANTOWN, Maryland, September 6, 2011 /PRNewswire/ --

- QIAGEN assay for JAK2 V617F mutation aims to identify patients more likely to respond to Lilly's 'JAK2 inhibitor' and to monitor responses to therapy

- Lilly will co-develop companion diagnostic

- QIAGEN's exclusive access to JAK2 biomarker underpins potential future expansion with additional Pharma compounds targeting gene

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not disclosed.

Lilly's proprietary compound, called a JAK2 inhibitor, targets the Janus kinase 2 (JAK2) gene, which has been shown to play a role in myeloproliferative neoplasms, a variety of blood cancers that cause blood cells to grow abnormally.

Under the terms of the agreement, QIAGEN will develop a new companion diagnostic test that will provide both qualitative and quantitative results for JAK2 V617F. The assay is intended to identify patients most likely to benefit from treatment with inhibitors of the pathway. The scope of the partnership includes development and use of the QIAGEN JAK2 assay during clinical trials and also covers manufacturing and joint commercialization of the diagnostic product in parallel with the Lilly compound.

QIAGEN gained exclusive access to the JAK2 biomarker through an agreement with Ipsogen, a French company that is a pioneer in profiling and biomarkers for leukemia and other blood cancers. In June, QIAGEN announced a proposal to fully acquire Ipsogen through a process that is under way. The JAK2 pathway is considered to bring high value to drug development in terms of defining and
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
2. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
3. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
4. QIAGEN Acquires Exclusive Licence for Key PI3K gene
5. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
6. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
7. Plexus Awarded Development Contract With QIAGEN
8. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
9. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
10. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
11. SciQuest Announces Strategic Alliance with QIAGEN
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 27, 2014 Scientists, researchers, ... for SPIE Laser Damage 2014 symposium. Marking ... for high-power lasers will run 14-17 September. The event ... optics and photonics . , The premier conference for ... laser damage to optical materials will engage researchers and ...
(Date:8/28/2014)... San Diego, CA (PRWEB) August 28, 2014 ... products, Pipette.com is offering a promotion for ... enables Pipette.com customers to purchase the highest quality ... Centrifuge Tubes are ideal for customers doing chemical, ... benefit lab technicians who are not regularly able ...
(Date:8/27/2014)... 2014 Rhythm, a biopharmaceutical company developing peptide ... result in metabolic disorders, announced today that it has ... U.S. Securities and Exchange Commission (SEC) relating to the ... stock. The number of shares to be offered and ... been determined. Citigroup and Cowen and Company ...
(Date:8/27/2014)... of nature,s mysteries is how plants survive impact ... the sun,s rays, while using this energy for ... in the plant,s blades quickly dissipate the energy ... quakes. Researchers at DTU Physics have now managed ... algae and bacteria contain light-absorbing proteins which play ...
Breaking Biology Technology:Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2DTU researchers film protein quake for the first time 2
... SAN DIEGO , April 22 Neurocrine Biosciences, Inc. (Nasdaq: ... 2010 financial results after the Nasdaq market closes on Wednesday, April 28, ... discuss its financial results and provide a Company update Thursday morning, April ... Pacific Time ). , , , ...
... 22 As evidence of its drive to ... activity, Smith & Nephew ( SNN, LSE: SN) Orthopaedics ... its VERILAST technology for knee replacement implants. After simulating ... knee replacement, VERILAST technology produced an 81-percent reduction* in ...
... , April 22 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... 29 at 4:30 p.m. Eastern Time to discuss its financial results for ... quarter financial results after market close. , , ... , , , ...
Cached Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results 2Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 2Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 3Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 4Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 5PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010 2
(Date:8/28/2014)... his collaborators have developed an online analytic tool that ... cells for biomedical investigation. CellNet is a free-use Internet ... cell engineering. Details of CellNet and its application to ... in the journal Cell . , "This free ... types of cell-based investigations and can potentially offer help ...
(Date:8/28/2014)... 2014  Privacy Advocate and Senior Staff Attorney at ... joins the lineup of biometric and mobile commerce experts ... Executive Summit in Tampa, Florida ... speakers include Steven Rahman, Director, Technology and Strategy at Samsung, ... The theme of this year,s event is Mobility at ...
(Date:8/28/2014)... August 28, 2014 Dyslexia, the most commonly ... a neurological reading disability that occurs when the ... don,t function normally. , The use of non-invasive ... activity is disrupted in dyslexia. However, most prior ... of brain regions, leaving a gap in our ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2Dyslexic readers have disrupted network connections in the brain 2
... have found that two genes already known to control ... They report their findings in the April issue of ... genes are required for a dividing cell's halves to ... be helpful in stopping the uncontrolled cell division found ...
... inflammation is linked to the development of certain ... premalignancy are not well understood. A new research ... Cell identifies B lymphocytes as important regulators of ... that drugs targeted against B lymphocytes or recruitment ...
... from Columbia University Medical Center have shown that a ... arteries during a heart attack does not improve patient ... commonly and successfully used during angioplasty in vein grafts ... the March 2 issue of the Journal of the ...
Cached Biology News:Pair of cancer genes found to drive both cell migration and division 2B cells are required for development of epithelial cancer associated with chronic inflammation 2Columbia study shows widely used artery clearing device does not help patients during heart attack 2
... AVOID FREEZE/THAW CYCLES. An assay kit designed ... Western blotting. PARP is an enzyme implicated ... apoptosis, PARP is cleaved by caspase-3. Cleavage ... to 85 kDa is a hallmark of ...
... These handy dispensers save ... glasses, wipers, hats, and other ... benchtop storage bins for small ... and manufacturing. Clear acrylic. Many ...
... handy dispensers save space and ... hats, and other garb. They ... bins for small parts used ... Clear acrylic. Open-slot design for ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Biology Products: